{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:58:00Z","timestamp":1778212680783,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.euroneuro.2018.05.006","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T10:07:05Z","timestamp":1530871625000},"page":"970-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25\u201350\u202fmg\/day) versus escitalopram (10\u201320\u202fmg\/day) in out-patients with severe generalized anxiety disorder"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7218-7810","authenticated-orcid":false,"given":"Dan J.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon-Paul","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Ahokas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Jarema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael.","family":"Van Ameringen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Vavrusova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"H\u04e7schl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan","family":"Bitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey N.","family":"Mosolov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Matharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Picarel-Blanchot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"de Bodinat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2018.05.006_bib0406","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th Edn (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0001","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000065127","article-title":"The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis","volume":"35","author":"Andrews","year":"2002","journal-title":"Psychopathology"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0002","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","article-title":"Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study","volume":"189","author":"Baldwin","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0400","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0004","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study","volume":"19","author":"Davidson","year":"2004","journal-title":"Depression Anxiety"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0006","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrd3140","article-title":"Agomelatine, the first melatonergic antidepressant: discovery, characterization and development","volume":"9","author":"de Bodinat","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0007","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jad.2004.11.011","article-title":"Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials","volume":"87","author":"Goodman","year":"2005","journal-title":"J Affect. Disord."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0008","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties","volume":"171","author":"Guardiola-Lemaitre","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0009","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"217","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0401","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/j.1440-1614.2006.01736.x","article-title":"Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome","volume":"40","author":"Haby","year":"2006","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0011","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/da.21937","article-title":"Generalizability of clinical trial results for generalized anxiety disorder to community samples","volume":"29","author":"Hoertel","year":"2012","journal-title":"Depression Anxiety"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0012","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/da.20257","article-title":"Human and economic burden of generalized anxiety disorder","volume":"25","author":"Hoffman","year":"2008","journal-title":"Depression Anxiety"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0013","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/archinte.161.6.875","article-title":"Clinical predictors of mental disorders among medical outpatients","volume":"161","author":"Jackson","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003592","article-title":"Antidepressants for generalized anxiety disorder","volume":"2","author":"Kapczinski","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/mpr.128","article-title":"Distinguishing generalized anxiety disorder from major depression: prevalence and impairment from current pure and comorbid disorders in the US and Ontario","volume":"11","author":"Kessler","year":"2002","journal-title":"Int. J Methods Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0016","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1017\/S0033291705004538","article-title":"Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication","volume":"35","author":"Kessler","year":"2005","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0402","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","article-title":"Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study","volume":"64","author":"Liebowitz","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0403","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/mpr.323","article-title":"Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder","volume":"19","author":"Matza","year":"2010","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0017","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0018","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.yic.0000137184.64610.c8","article-title":"Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study","volume":"19","author":"Montgomery","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0404","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jbtep.2007.10.010","article-title":"Suicidal ideation and anxiety disorders: elevated risk or artifact of comorbid depression?","volume":"39","author":"Norton","year":"2008","journal-title":"J. Behav. Ther. Exp. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0019","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09540260500104524","article-title":"Sleep disturbance in anxiety disorders","volume":"17","author":"Papadimitriou","year":"2005","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00434408","article-title":"The leeds sleep evaluation questionnaire in psychopharmacological investigations \u2013 a review","volume":"71","author":"Parrott","year":"1980","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0405","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamapsychiatry.2017.0056","article-title":"Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe","volume":"74","author":"Ruscio","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0021","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jpsychores.2006.04.012","article-title":"A new approach to the construct of alertness","volume":"60","author":"Shapiro","year":"2006","journal-title":"J. Psychosom. Res."},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2018.05.006_bib0022","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0023","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.167.1.99","article-title":"A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale","volume":"167","author":"Snaith","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0024","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.euroneuro.2017.02.007","article-title":"Efficacy and safety of agomelatine (10 or 25 mg\/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study","volume":"27","author":"Stein","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study","volume":"75","author":"Stein","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0026","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4088\/JCP.11m07493","article-title":"Agomelatine prevents relapse in generalised anxiety disorder: a 6-month placebo-controlled discontinuation study","volume":"73","author":"Stein","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0027","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","article-title":"Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Stein","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0028","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10401230590932335","article-title":"Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes","volume":"17","author":"Stein","year":"2005","journal-title":"Ann. Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0029","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s12325-011-0071-8","article-title":"Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder","volume":"28","author":"Stein","year":"2011","journal-title":"Adv. Ther."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.2294","article-title":"Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression","volume":"28","author":"Stein","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0031","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/da.10065","article-title":"Generalized anxiety disorder: prevalence, burden, and cost to society","volume":"16","author":"Wittchen","year":"2002","journal-title":"Depression Anxiety"},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0032","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0033","unstructured":"World Medical Association, 2013. Declaration of Helsinki. In: p. Revision 2013."},{"key":"10.1016\/j.euroneuro.2018.05.006_bib0034","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18301214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18301214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:51:34Z","timestamp":1760377894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X18301214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0924977X18301214"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.05.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25\u201350\u202fmg\/day) versus escitalopram (10\u201320\u202fmg\/day) in out-patients with severe generalized anxiety disorder","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}